AMGN compared with VYGR: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

VYGRVoyager Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

VYGRVoyager Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

AMGNAmgen Inc

468.74▼−2.03%

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

VYGRVoyager Therapeutics, Inc.

1.70▼−8.90%

Regular sessionNov 5 '26

Mkt cap$115.2MRevenue$3MQ2 FY26Revenue$40MFY25

Compare

Regular sessionNov 5 '26

AMGNAmgen Inc

VYGRVoyager Therapeutics, Inc.

468.74▼−2.03%

Price

1.70▼−8.90%

$258.8B

Mkt cap

$115.2M

Q3 FY26$10.4B

Revenue

$3MQ2 FY26

FY25$36.8B

Revenue

$40MFY25

AMGN468.74▼−2.03%vsVYGR1.70▼−8.90%Regular sessionNov 5 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

VYGR: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only VYGR 2

NBIXNeurocrine Biosciencescustomer

NVSNovartis Pharmacustomer

Role chip = supplier or customerSource: SEC EDGAR

Price

rebased to 0%

AMGN, solidVYGR, dashed